Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways

Experimental Hematology

Volumn 42, Issue 10, 2014, Pages 883-896

  Pandey, Manoj K ^a   Kale, Vijay P ^a   Song, Chunhua ^a   Sung, Shen shu ^a   Sharma, Arun K ^a   Talamo, Giampaolo ^a   Dovat, Sinisa ^a   Amin, Shantu G ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; GAMBOGIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; STROMAL CELL DERIVED FACTOR 1ALPHA; SYNAPTOPHYSIN; SYNAPTOTAGMIN I; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR PROTEIN; XANTHONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CHEMOTAXIS; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ETIOLOGY; GARCINIA MANGOSTANA; GENETICS; METABOLISM; MYELOPOIESIS; OSTEOLYSIS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PHYTOTHERAPY; PREVENTION AND CONTROL; PROTEIN PROCESSING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CXCL12; CHEMOTAXIS; CHROMATIN IMMUNOPRECIPITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; GARCINIA MANGOSTANA; HUMANS; MACROPHAGES; MICE; MULTIPLE MYELOMA; MYELOPOIESIS; NEOPLASM PROTEINS; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; PHOSPHORYLATION; PHYTOTHERAPY; PROMOTER REGIONS, GENETIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; RECEPTORS, CXCR4; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; XANTHONES;

EID: 84908384269     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.07.261     Document Type: Article

References (66)

1. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364:1046-1060.
2. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003, 78:21-33.
3. Terpos E., Kastritis E., Dimopoulos M.A. Prevention and treatment of myeloma bone disease. Curr Hematol Malign Rep 2012, 7:249-257.
4. Terpos E., Roodman G.D., Dimopoulos M.A. Optimal use of bisphosphonates in patients with multiple myeloma. Blood 2013, 121:3325-3328.
5. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.
6. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23:879-894.
7. Li S., Huang S., Peng S.B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005, 27:1329-1339.
8. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003, 170:1136-1140.
9. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007, 256:137-165.
10. Alsayed Y., Ngo H., Runnels J., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109:2708-2717.
11. Hideshima T., Chauhan D., Hayashi T., et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Molec Canc Therapeu 2002, 1:539-544.
12. Trentin L., Miorin M., Facco M., et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol 2007, 138:594-602.
13. Moller C., Stromberg T., Juremalm M., Nilsson K., Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003, 17:203-210.
14. Semerad C.L., Christopher M.J., Liu F., et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
15. Grassi F., Piacentini A., Cristino S., et al. Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol 2003, 120:391-400.
16. Le Y., Zhou Y., Iribarren P., Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 2004, 1:95-104.
17. Wright L.M., Maloney W., Yu X., Kindle L., Collin-Osdoby P., Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone 2005, 36:840-853.
18. Zannettino A.C., Farrugia A.N., Kortesidis A., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 2005, 65:1700-1709.
19. Grassi F., Cristino S., Toneguzzi S., Piacentini A., Facchini A., Lisignoli G. CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 2004, 199:244-251.
20. Diamond P., Labrinidis A., Martin S.K., et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res 2009, 24:1150-1161.
21. Leucht P., Temiyasathit S., Russell A., et al. CXCR4 antagonism attenuates load-induced periosteal bone formation in mice. J Orthop Res 2013, 31:1828-1838.
22. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525.
23. Prasad S., Pandey M.K., Yadav V.R., Aggarwal B.B. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis. Cancer Prev Res (Phila) 2011, 4:1084-1094.
24. Zhu X., Zhang H., Lin Y., et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferrin receptors. J Chemother 2009, 21:666-672.
25. Mu R., Lu N., Wang J., et al. An oxidative analogue of gambogic acid-induced apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its anticancer activity invitro. Eur J Cancer Prev 2010, 19:61-67.
26. He D., Xu Q., Yan M., et al. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009, 9:343.
27. Gu H., Rao S., Zhao J., et al. Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 2009, 135:1777-1782.
28. Xu X., Liu Y., Wang L., et al. Gambogic acid induces apoptosis by regulating the expression of Bax and Bcl-2 and enhancing caspase-3 activity in human malignant melanoma A375 cells. Int J Dermatol 2009, 48:186-192.
29. Wang X., Chen Y., Han Q.B., et al. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 2009, 9:242-253.
30. Qi Q., You Q., Gu H., et al. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol 2008, 117:433-438.
31. Wu Z.Q., Guo Q.L., You Q.D., Zhao L., Gu H.Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells invivo and invitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004, 27:1769-1774.
32. Gu H., You Q., Liu W., et al. Gambogic acid induced tumor cell apoptosis by T lymphocyte activation in H22 transplanted mice. Int Immunopharmacol 2008, 8:1493-1502.
33. Sung B., Cho S.G., Liu M., Aggarwal B.B. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling. Int J Cancer 2011, 129:2062-2072.
34. Ding W., You H., Dang H., et al. Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion. Hepatology 2010, 52:945-953.
35. Vande Broek I., Leleu X., Schots R., et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica 2006, 91:200-206.
36. Friesner R.A., Banks J.L., Murphy R.B., et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47:1739-1749.
37. Halgren T.A., Murphy R.B., Friesner R.A., et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004, 47:1750-1759.
38. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., Mee R.P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Computer-Aided Molecul Des 1997, 11:425-445.
39. Wu B., Chien E.Y., Mol C.D., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
40. Marchese A., Benovic J.L. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. J Bol Chem 2001, 276:45509-45512.
41. Bhandari D., Trejo J., Benovic J.L., Marchese A. Arrestin-2 interacts with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4. J Biol Chem 2007, 282:36971-36979.
42. Helbig G., Christopherson K.W., Bhat-Nakshatri P., et al. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003, 278:21631-21638.
43. Azab A.K., Runnels J.M., Pitsillides C., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
44. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931.
45. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci US A 1998, 95:3597-3602.
46. Li J., Sarosi I., Yan X.Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000, 97:1566-1571.
47. Lai F.P., Cole-Sinclair M., Cheng W.J., et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004, 126:192-201.
48. Chikatsu N., Takeuchi Y., Tamura Y., et al. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation invitro. Biochem Biophys Res Commun 2000, 267:632-637.
49. Zhang J., Dai J., Qi Y., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001, 107:1235-1244.
50. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
51. Tang C.H., Chuang J.Y., Fong Y.C., Maa M.C., Way T.D., Hung C.H. Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 2008, 29:1483-1492.
52. Fernandis A.Z., Prasad A., Band H., Klosel R., Ganju R.K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23:157-167.
53. Gschwind A., Prenzel N., Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002, 62:6329-6336.
54. Schioppa T., Uranchimeg B., Saccani A., et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003, 198:1391-1402.
55. Kulbe H., Hagemann T., Szlosarek P.W., Balkwill F.R., Wilson J.L. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005, 65:10355-10362.
56. Bachelder R.E., Wendt M.A., Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002, 62:7203-7206.
57. Richard C.L., Blay J. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner. Int J Oncol 2007, 30:1215-1222.
58. Zhang L., Yi Y., Chen J., et al. Gambogic acid inhibits Hsp90 and deregulates TNF-alpha/NF-kappaB in HeLa cells. Biochem Biophys Res Commun 2010, 403:282-287.
59. Suzuki E., Daniels T.R., Helguera G., Penichet M.L., Umezawa K., Bonavida B. Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. Int J Oncol 2010, 36:1299-1307.
60. Palempalli U.D., Gandhi U., Kalantari P., et al. Gambogic acid covalently modifies IkappaB kinase-beta subunit to mediate suppression of lipopolysaccharide-induced activation of NF-kappaB in macrophages. Biochem J 2009, 419:401-409.
61. Geng J., Xiao S., Zheng Z., Song S., Zhang L. Gambogic acid protects from endotoxin shock by suppressing pro-inflammatory factors invivo and invitro. Inflamm Res 2013, 62:165-172.
62. Gazitt Y., Akay C. Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 2004, 22:65-73.
63. Kim S.Y., Lee C.H., Midura B.V., et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201-211.
64. Yu X., Huang Y., Collin-Osdoby P., Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003, 18:1404-1418.
65. Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 2003, 8:469-488.
66. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221-1228.